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Abstract 
Objective:  
To determine whether modifying an outcome definition to remove subjective elements reduced bias 
in a trial that could not use blinded outcome assessment.  
 
Study setting and design:  
Re-analysis of an open-label trial comparing a restrictive vs. liberal transfusion strategy for 
gastrointestinal bleeding. The usual definition of the primary outcome, further bleeding, allows 
subjective clinical symptoms to be used alone for diagnosis, whereas the definition used in the trial 
required more objective confirmation by endoscopy. We compared treatment effect estimates for 
these two definitions. 
 
Results: 
Fewer subjective symptom-identified events were confirmed using more objective methods in the 
restrictive arm (18%) than in the liberal arm (56%), indicating differential assessment between arms. 
An analysis using all events (both subjective and more objective) led to an odds ratio of 0.83 (95% CI: 
0.50-1.37). When only events confirmed using more objective methods were included, the odds 
ratio was 0.50 (95% CI: 0.32-0.78). The ratio of the odds ratios was 1.66, indicating that including 
unconfirmed events in the definition biased the treatment effect upwards by 66%.  
 
Conclusion: 
Modifying the outcome definition to exclude subjective elements substantially reduced bias. This 
may be a useful strategy for reducing bias in trials that cannot blind outcome assessment.  
 
Keywords: Bias, open-label trial, blinding, outcome assessment, randomized controlled trial, cluster-
randomized. 
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What is new: 
 
Key findings 
 Blinded outcome assessment in clinical trials is not always feasible but including subjective 
elements can produce bias in estimated treatment effects.  
 We modified the outcome definition of further bleeding in an open-label, cluster 
randomised trial of gastrointestinal bleeding to omit subjective elements, resulting in a 
definition using more objective measures.  
 Re-analysis of the trial data-set found that the modified definition which excluded subjective 
elements reduced bias by up to 66%. 
 
What this adds to what is known 
 Modifying the outcome definition to exclude subjective elements can reduce bias when 
unblinded assessment is unavoidable. 
 
What is the implication, what should change now 
 Modifying trial endpoints to exclude subjective elements can be a useful strategy when 
designing open-label trials where blinded outcome assessment is not possible.  
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1. Background 
Blinded outcome assessment is a key component of randomised controlled trials, as unblinded 
assessment can result in substantial bias in the estimated treatment effects [1-7]. However, blinded 
assessment can be difficult to achieve under some circumstances. For example, TRIGGER 
(Transfusion in Gastrointestinal Bleeding) was an open-label cluster-randomised trial that assessed 
the feasibility of implementing two red blood cell transfusion strategies (restrictive vs. liberal) in 
patients admitted to UK hospitals with acute upper gastrointestinal bleeding (AUGIB) [8-10]. The 
primary clinical outcome was an episode of further bleeding arising from the patient’s upper 
gastrointestinal tract. In open-label trials, blinded outcome assessment can often be achieved by 
having a third party (e.g. another clinician at the hospital) who is unaware of treatment allocation 
assess the patient, or by sending the relevant information to a central (blinded) adjudication 
committee for assessment. However, neither of these options was feasible in TRIGGER [11]. Because 
cluster randomisation was used, every clinician within each trial site was aware of the treatment 
allocation in that hospital, and therefore having a third party assess the patient directly was 
impossible. Equally, it was not possible to compile relevant information in a blinded manner for 
review by an independent adjudication committee [11]. Therefore, assessment of further bleeding 
could not be done in a blinded manner in TRIGGER.  
 
There is little guidance on methods to reduce the risk of bias when blinded outcome assessment is 
infeasible. One approach would be to modify the outcome to make it easier to implement blinded 
assessment. However, in some circumstances the only modification that is possible is to use a 
surrogate measure in place of a clinically important outcome. Surrogate measures are not always 
useful indicators of clinical benefits or harms, and may not be directly relevant to patients or 
clinicians [12, 13]. For example, the occurrence of a further bleeding episode in TRIGGER could have 
been based on biomarkers, such as a drop in a patient’s haemoglobin count, which could easily have 
been adjudicated by a blinded committee. However, this may be a misleading surrogate for further 
bleeding since the count may not change during the acute phase of haemorrhage and therefore 
would have been of limited clinical relevance. 
 
An alternative approach is to modify the outcome definition to make it less subjective, which can 
reduce bias while retaining the clinical value of the outcome measure [11]. This second approach 
was used in TRIGGER. The definition of further bleeding was modified from that used in routine 
clinical practice to exclude subjective elements. The resulting definition only included more objective 
measures of further bleeding [11].  
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We assessed whether modifying an outcome definition can reduce bias using TRIGGER as a case 
study. We re-analysed the TRIGGER trial to compare two outcome definitions, the usual definition, 
which included subjective elements, and the modified definition used in TRIGGER, which excluded 
subjective elements.  
 
 
2. Methods 
2.1 Choice of outcome measure in TRIGGER 
TRIGGER (ISRCTN 85757829) was a cluster-randomised trial that compared the feasibility of 
implementing two red blood cell transfusion strategies for patients admitted to UK hospitals with 
AUGIB. In both strategies, patients received a transfusion when their haemoglobin dropped below a 
certain level, which was 8 g/dL under the restrictive transfusion policy and 10 g/dL under the liberal 
transfusion policy. It was impossible to blind the trial personnel as the intervention involved blood 
transfusion in an emergency setting. Our previous publication explains why a blinded outcome 
assessment was not feasible [11]. The standard of care for managing a patient with AUGIB is 
resuscitation and stabilisation, followed by direct visual inspection of the upper gastrointestinal tract 
with a fibre optic telescope, called an endoscopy, to identify and treat the source of bleeding. 
 
The primary clinical outcome was further bleeding up to day 28. It was defined as either ongoing 
bleeding at the end of the initial endoscopy or a bleed that restarted after stopping, as per standard 
international consensus criteria [14]. Further bleeding can be assessed either using a patient’s 
physical signs and symptoms, or by a visual inspection of the upper gastrointestinal tract using 
endoscopy. Assessment based on patient symptoms considers haemodynamic instability (e.g. low 
blood pressure and an increased heart rate), a drop in the haemoglobin concentration, whether the 
patient has vomited blood, and the passage of altered blood per rectum. In visual inspection, the 
patient’s upper gastrointestinal tract is examined during an endoscopy to determine whether there 
is ongoing bleeding in the stomach.  
We consider an outcome to be subjective if (a) its assessment depends on the judgement of the 
assessor; and (b) this judgement may be influenced by knowledge of the patient’s treatment 
assignment [15]. Assessment of further bleeding based on patient symptoms inherently involves a 
degree of subjectivity. For example, signs of haemodynamic instability can be mimicked by other 
conditions such as sepsis, dehydration, or intercurrent illness. The clinician must judge whether the 
haemodynamic instability is caused by further bleeding or something else. The haemoglobin 
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concentration may drop due to a delayed response following the initial bleed, haemodilution after 
fluid infusion, another factor, or a combination. Again, the clinician must judge the cause of the 
concentration drop. If a patient vomits altered blood (“coffee grounds” rather than fresh red blood) 
or passes dark altered blood per rectum (which can often persist for up to 5 days after the initial 
bleed), the clinician must decide whether the blood is recent or old. Recent blood indicates a new or 
ongoing bleed, whereas old blood may originate from the initial bleed for which the patient 
attended the hospital.  
 
In contrast, assessment of further bleeding using endoscopy is far less subjective, as it does not 
require the clinician to judge the “degree” of what they see. Instead, they simply determine the 
presence or absence of ongoing bleeding in the upper gastrointestinal tract. Assessment via 
endoscopy is therefore a more objective endpoint, as it should reduce the potential for 
ascertainment bias compared with an assessment based on clinical symptoms alone.  
 
In clinical practice, further bleeding may initially be suspected based on clinical symptoms or may be 
identified directly during the patient’s initial endoscopy (e.g. if there is still ongoing bleeding after a 
therapeutic procedure has been undertaken to try to stop the bleed). If further bleeding is suspected 
based on clinical symptoms, then an endoscopy is typically undertaken to confirm that the 
symptoms are the result of further bleeding, rather than the original bleed or another condition, and 
to attempt to treat the bleeding lesion.  
 
There are therefore three possible outcomes of the assessment of a further bleeding episode: 
1. Unconfirmed events suspected from patient symptoms: A further bleeding episode is 
suspected from patient symptoms, but is not confirmed through an endoscopy  
2. Confirmed events suspected from patient symptoms: A further bleeding episode is 
suspected from patient symptoms and is confirmed with an endoscopy 
3. Confirmed events identified during endoscopy: A further bleeding episode is identified 
directly during an endoscopy 
 
Unconfirmed events suspected from patient symptoms typically occur when a subsequent 
endoscopy shows no evidence of further bleeding. The patient symptoms instead result from either 
the original bleed for which the patient presented to the hospital or some other medical condition. 
However, in rare cases a suspected event may not be confirmed because a follow-up endoscopy is 
not performed. This may occur if further intervention is deemed not to be in the patient’s best 
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interests, such as on grounds of futility if the patient is likely to die in the near future due to co-
morbidity. Confirmed events are true further bleeding events, as regardless of why they are initially 
suspected, they are confirmed during an endoscopy.  
 
As TRIGGER was an open-label trial, participating clinicians may have assessed suspected further 
bleeding episodes differently depending on the treatment arm. For example, the clinicians may have 
had pre-conceptions about the effectiveness of one treatment policy over another and may 
therefore have been more likely to view patient symptoms such as a drop in the haemoglobin 
concentration or vomiting blood as indicative of a new bleeding episode, rather than an old one. This 
type of ascertainment bias for subjective outcomes has been recorded in a variety of situations [1-5]. 
In this scenario, including unconfirmed bleeding events suspected from patient symptoms (i.e. 
events that were not confirmed using more objective means) in the analysis would have led to 
biased estimates of the treatment effect. Further bleeding episodes in TRIGGER thus required more 
objective confirmation. The primary analysis for further bleeding only included events that were 
confirmed with an endoscopy, both those directly identified during an endoscopy and those that 
were initially suspected from patient symptoms.  
 
This article presents a re-analysis of the TRIGGER trial to determine (a) the number of further 
bleeding episodes suspected from clinical signs that were not confirmed using more objective 
methods, and whether this number differed according to the treatment arm (indicating 
ascertainment bias); and (b) whether an analysis that included both confirmed and unconfirmed 
events led to bias in the estimated treatment effect, compared with the analysis that required more 
objective confirmation of every suspected event.  
 
2.2 Statistical methods 
We summarised the number of further bleeding episodes suspected from patient symptoms that 
were not confirmed using more objective methods separately for each treatment arm. We 
estimated the treatment effects (expressed as odds ratios), 95% confidence intervals, and p-values 
using two definitions for further bleeding episodes:  
 
 Excluding unconfirmed events: This outcome included: 
o Confirmed events suspected from patient symptoms 
o Confirmed events identified during endoscopy 
 Including unconfirmed events: This outcome included: 
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o Confirmed events suspected from patient symptoms 
o Confirmed events identified during endoscopy 
o Unconfirmed events suspected from patient symptoms 
 
We analysed both definitions of further bleeding using a logistic regression model, adjusted for 
baseline covariates (age, the number of co-morbidities, presence of shock, and coagulopathy) [16]. 
We used generalised estimating equations to account for clustering by hospital [17]. The treatment 
effect estimates were expressed as the restrictive transfusion policy vs. liberal transfusion policy. An 
odds ratio less than 1 indicated a beneficial effect of the restrictive transfusion policy. An odds ratio 
greater than 1 indicated a beneficial effect of the liberal transfusion policy. We compared the odds 
ratios for the two outcome definitions by calculating a ratio of odds ratios (ROR), by dividing the 
odds ratio obtained from the analysis that included unconfirmed events by the odds ratio obtained 
from the analysis that excluded unconfirmed events. 
 
The ROR gives a measure of the bias introduced by including episodes that were not confirmed using 
more objective methods. An ROR of 1 indicates no bias, an ROR<1 indicates bias in favour of the 
restrictive transfusion policy, and an ROR>1 indicates bias in favour of the liberal transfusion policy.  
 
As discussed earlier, in rare cases, unconfirmed events suspected from patient symptoms can occur 
because a follow-up endoscopy was not performed after an episode of further bleeding was 
suspected based on patient symptoms. This situation can occur if further intervention is deemed to 
not be in the patient’s best interests, such as on grounds of futility if the patient is likely to die in the 
near future due to co-morbidity. It is then unclear whether the initial assessment of further bleeding 
based on patient symptoms is correct or not. In TRIGGER, we did not record whether an endoscopy 
was explicitly performed to confirm a suspected bleeding event. We therefore cannot say with 
certainty that all unconfirmed events suspected from patient symptoms were because the 
endoscopy showed no signs of further bleeding. A small number of unconfirmed events may have 
occurred because no confirmatory endoscopy was undertaken due to the patient’s health status, 
although this event is uncommon [18]. We therefore performed a sensitivity analysis [19], in which 
we reclassified unconfirmed events suspected from patient symptoms as confirmed events if the 
patient died within one week of the unconfirmed bleeding event.  
 
A patient with severe bleeding may undergo interventional radiology or surgery to confirm and treat 
the lesion, rather than endoscopy. For simplicity, we have referred to further bleeding events 
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confirmed either by endoscopy, radiology, or surgery as events that were confirmed using more 
objective methods. 
 
The re-analyses presented here are exploratory and should not be used to make inferences about 
the effectiveness of a restrictive or liberal approach to red blood cell transfusion in patients with 
AUGIB. 
 
3. Results 
3.1 TRIGGER data 
Further bleeding data at 28 days were available for 905 patients, 393 of whom were on the 
restrictive policy and 512 on the liberal policy. As shown in Figure 1, there were 27 further bleeding 
events in the restrictive transfusion arm, of which 14 were suspected based on patient symptoms 
but were not confirmed using more objective methods, 3 were suspected based on patient 
symptoms and were confirmed using more objective methods and 10 were discovered directly 
during an endoscopy. In comparison, there were 42 further bleeding episodes in the liberal 
transfusion group, of which 11 were suspected from patient symptoms but were not confirmed 
using more objective methods, 14 were based on patient symptoms and were confirmed using more 
objective methods, and 17 were discovered directly during an endoscopy (Figure 1).  
 
There were 17 occurrences of further bleeding that were initially suspected based on patient 
symptoms in the restrictive group and 25 in the liberal group. A significantly lower proportion of 
these events were confirmed using more objective methods in the restrictive arm than in the liberal 
arm (restrictive 3/17 (18%) vs. liberal 14/25 (56%), ratio 0.32, 95% CI 0.11 to 0.93).  
 
3.2 Including unconfirmed events biased the treatment effect 
The analysis that included unconfirmed events (i.e. included unconfirmed events suspected from 
patient symptoms in addition to events confirmed by an endoscopy) analysed 27/393 events (7%) in 
the restrictive group and 42/512 (8%) in the liberal group, giving an odds ratio of 0.83 (95% CI: 0.50 
to 1.37, p = 0.47). The analysis that excluded unconfirmed events (i.e. included only events 
confirmed by an endoscopy) analysed 13/393 events (3%) in the restrictive group and 31/512 (6%) in 
the liberal group, giving an odds ratio of 0.50 (95% CI: 0.32 to 0.78, p = 0.002).  
 
The definition which included unconfirmed events indicated a small difference between treatment 
groups that was not statistically significant. In contrast, the definition which excluded unconfirmed 
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events found a large reduction in further bleeding episodes, which was statistically significant. The 
ROR was 1.66, indicating that the analysis which included unconfirmed events as part of the primary 
outcome biased the treatment effect upwards by 66% in favour of the liberal transfusion arm.  
 
3.3 Sensitivity analysis 
Of the patients who had an unconfirmed further bleeding event that was initially suspected based 
on their symptoms, 2/11 (18%) in the liberal arm and 2/14 (14%) in the restrictive arm died within a 
week of the suspected bleed. These events were therefore more likely to have remained 
unconfirmed due to the patients’ ill health, rather than being ruled out as further bleeding with an 
endoscopy. A sensitivity analysis that reclassified these bleeding episodes as confirmed found similar 
results to the original analysis; the odds ratio for confirmed bleeding episodes was 0.53 (95% CI 0.34 
to 0.83, p = 0.005) and the ROR was 1.57.  
 
 
4. Discussion 
Blinded outcome assessment is sometimes difficult to achieve in open-label trials. A recent review 
found that only 26% of open-label trials reported using blinded outcome assessment [20]. Unblinded 
outcome assessment can lead to biased estimates of treatment effect when the assessment of the 
outcome measure is subjective. The outcome definition can be modified to remove subjective 
elements, as was done in the TRIGGER trial [11]. However, it is unclear how much of a difference this 
approach makes in practice. We re-analysed the TRIGGER trial to assess whether modifying the usual 
outcome definition for further bleeding to exclude subjective events based solely on patient 
symptoms had effectively reduced bias.  
 
We found that a substantially higher proportion of subjective events were not confirmed using more 
objective methods in the restrictive arm than in the liberal arm, indicating differential assessment 
between the treatment groups. Clinicians’ preconceived expectations of the efficacy of the two 
interventions may have driven this difference. Previous research has shown that bias associated with 
unblinded outcome assessment is often in the direction of the assessors’ expectations. For example, 
if assessors expect an intervention to perform better than its control, they will typically assess the 
intervention patients as having done better than the control patients [21]. The clinicians involved in 
TRIGGER may have expected the liberal transfusion policy to lead to better patient outcomes than 
the restrictive policy, as the liberal policy more closely reflects usual clinical practice.  
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The differential assessment in the treatment arms led to substantially different results when 
unconfirmed events were included or excluded. Including unconfirmed events in the outcome 
definition biased the treatment effect upwards by 66%. The statistically significant difference found 
in favour of the restrictive transfusion arm thus became non-significant. The strategy of modifying 
outcome definitions to exclude subjective elements in open-label trials where blinded outcome 
assessment is not feasible is thus a useful option for researchers to consider in order to reduce bias.  
 
It should be noted that modifying an outcome definition may have other implications for the trial 
apart from a reduction in bias. Excluding (or including) some elements in the outcome definition will 
have implications for precision and power. For example, in TRIGGER the number of events was 
reduced from 69 to 44 after redefining the endpoint. This can have implications for sample size 
calculations, which depend on the number of events (for time-to-event outcomes) or the proportion 
of patients experiencing an event (for binary outcomes). A reduction in the number or proportion of 
events will typically lead to larger sample size requirements. However, it is not necessarily the case 
that including additional elements in the definition will increase power; if these extra elements are 
not representative of the underlying ‘true’ outcome (e.g. are poor surrogates) then incorporating 
them in the outcome definition will actually reduce precision, and hence require larger sample sizes.   
 
Another important consideration is the clinical relevance of the outcome definition. Excluding (or 
including) some elements in the outcome definition will have implications for how meaningful the 
outcome is to patients and clinicians. For example, in TRIGGER, further bleeding could have been 
defined based on a drop in the patient’s haemoglobin level, which could have easily been assessed 
by a blinded committee. However, this is a poor surrogate outcome for further bleeding, and so 
although such a definition would have led to an unbiased estimate, it would not have accurately 
reflected the underlying clinical condition. Therefore, when modifying an outcome definition it is 
important to ensure that the clinical relevance of the outcome is retained.  
 
One limitation of this work is that we have assumed that all episodes of further bleeding were 
identified, either based on clinical suspicion or directly during an endoscopy. However, it is possible 
that some events were missed; for example, a patient may have had a further bleeding episode, but 
the symptoms were sufficiently mild that the clinician did not suspect a further bleeding event. The 
estimated odds ratios from both analyses may have differed slightly had these events been included, 
and as such, the ratio of odds ratios may also have differed.  
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5. Conclusion 
Modifying the outcome definition to exclude subjective elements led to a substantial reduction in 
bias in the TRIGGER trial. This may be a useful strategy to adopt for open-label trials where blinded 
outcome assessment is not feasible.  
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Figure 1 – Treatment effect estimates in TRIGGER under different outcome definitions 
 
*This figure shows the number of events for each treatment arm in TRIGGER under two different outcome definitions: (a) including all further bleeding 
events; and (b) including only further bleeding events confirmed by endoscopy or another more objective method.  
 
 
